Swiss pharma giant Roche acquired Ireland’s Inflazome and the company’s NLRP3 inflammasome inhibitors aimed at multiple inflammatory diseases.

Immunomedics Inc.’s cancer drug Trodelvy, which received accelerated U.S. regulatory approval in April 2020, extended survival time in previously treated patients with an advanced form of breast cancer in a clinical trial.

In anticipation of data from a Phase III vaccine candidate study potentially becoming available in October, Germany’s BioNTech acquired a manufacturing facility from Novartis to boost production capabilities for the preventative treatment for the novel coronavirus.

Bayer secured the rights to an experimental breast cancer drug developed by U.S. biotech firm Systems Oncology LLC in a deal worth up to $370 million.

Seattle Genetics’ shares rocketed after news broke of Merck making a major investment into the Bothwell, Washington-based company via two strategic oncology deals.

Gilead Sciences Inc. is nearing a deal to buy biopharmaceutical company Immunomedics Inc. for more than $20 billion in a deal that would further expand Gilead’s portfolio of cancer treatments, the Wall Street Journal reported on Saturday.

The U.S. government will send an “overwhelming majority” of the rapid Covid-19 tests purchased from Abbott Laboratories to governors of states and territories to support school reopenings and other critical tasks, an administration official said at a press briefing.

Two years after nabbing three novel anti-infective drug candidates from Novartis for the treatment of antibiotic-resistant infections, Boston Pharmaceuticals struck a deal with the Swiss pharma giant for a potential treatment for non-alcoholic steatohepatitis (NASH).

Novavax entered into an agreement to provide the United Kingdom with 60 million doses of the company’s Covid-19 vaccine candidate should NVX-CoV2373 be approved, as well as a late-stage efficacy study in the U.K.

The United States is tying payments for Covid-19 vaccines to timing milestones for production and approval, according to public documents and a Trump administration official, putting pressure on drugmakers including Moderna Inc. to meet ambitious targets.